Clinical Trial

EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) . This clinical trial will include solid tumor patients who failed standard treatment. The main questions to answer are: Safety of EVM16. Suitable dose of EVM16. Effects of EVM16 combined with tislelizumab.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-02; most recent amendment 2026-06-17.
Status change: Not Yet Recruiting → Recruiting 2025-03-13
Trial Details
NCT Number NCT06541639
Lead Sponsor Peking University
Collaborators: Shanghai Cancer Centre, Everest Medicines (China) Co.,Ltd.
Conditions Advanced or Recurrent Solid Tumors
Enrollment 78 participants
Start Date 2025-03-04
Primary Completion 2028-03 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-22